Bicalutamide, bearing the CAS number 90357-06-5, is a sophisticated chemical compound with significant implications in pharmaceutical research and development. Characterized as a non-steroidal antiandrogen, its molecular structure facilitates a specific interaction with the androgen receptor (AR). This makes it an invaluable tool for investigating and treating conditions driven by androgen signaling, most notably prostate cancer. Its chemical properties, including its molecular formula (C18H14F4N2O4S) and molecular weight (430.37), are well-documented, ensuring precise application in scientific endeavors.

The demand for bicalutamide powder for research is substantial, as it serves as a primary agent in studies aimed at understanding hormone receptor antagonists. High-quality, medical grade bicalutamide bulk drug is essential for ensuring the accuracy and reliability of research outcomes. As a critical antineoplastic chemical medicine raw material, it underpins the synthesis of various therapeutic agents and contributes to the broader oncology landscape.

The specific function of Bicalutamide as an androgen receptor inhibitor prostate cancer treatment is well-established. Its precise mechanism involves blocking the binding of androgens to the receptor, thereby impeding cancer cell proliferation. Beyond its clinical applications, the compound is frequently used in laboratory settings to explore cellular pathways and drug resistance mechanisms. This makes Bicalutamide CAS 90357-06-5 a compound of dual importance: a therapeutic agent and a vital research chemical.

The continued exploration of Bicalutamide’s properties and potential applications underscores its significance in medicinal chemistry. Researchers worldwide rely on its availability and well-defined characteristics to advance the development of new therapies and enhance our understanding of complex biological processes. Its role as a foundational pharmaceutical intermediate cements its place in scientific advancement.